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Repetitive mild traumatic brain injury (rmTBI) is a major epigenetic risk factor for
Alzheimer’s disease (AD). The precise nature of how rmTBI leads to or precipitates
AD pathology is currently unknown. Numerous neurological conditions have shown
an important role for dysfunctional phospholipid metabolism as a driving factor for
the pathogenesis of neurodegenerative diseases. However, the precise role in rmTBI
and AD remains elusive. We hypothesized that a detailed phospholipid characterization
would reveal profiles of response to injury in TBI that overlap with age-dependent
changes in AD and thus provide insights into the TBI-AD relationship. We employed
a lipidomic approach examining brain phospholipid profiles from mouse models of
rmTBI and AD. Cortex and hippocampal tissue were collected at 24 h, 3, 6, 9, and
12 months post-rmTBI, and at ages representing ‘pre’, ‘peri’ and ‘post’ onset of
amyloid pathology (i.e., 3, 9, 15 months-old). Total levels of phosphatidylcholine (PC),
phosphatidylethanolamine (PE), LysoPE, and phosphatidylinositol (PI), including their
monounsaturated, polyunsaturated and saturated fatty acid (FA) containing species
were significantly increased at acute and/or chronic time points post-injury in both brain
regions. However, levels of most phospholipid species in PS1/APP mice were nominal
in the hippocampus, while in the cortex, levels were significantly decreased at ages
post-onset of amyloid pathology. Sphingomyelin and LysoPC levels showed coincidental
trends in our rmTBI and AD models within the hippocampus, an increase at acute
and/or chronic time points examined. The ratio of arachidonic acid (omega-6 FA) to
docosahexaenoic acid (omega-3 FA)-containing PE species was increased at early time
points in the hippocampus of injured versus sham mice, and in PS1/APP mice there was
a coincidental increase compared to wild type littermates at all time points. This study
demonstrates some overlapping and diverse phospholipid profiles in rmTBI and AD
models. Future studies are required to corroborate our findings in human post-mortem
tissue. Investigation of secondary mechanisms triggered by aberrant downstream
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alterations in bioactive metabolites of these phospholipids, and their modulation at
the appropriate time-windows of opportunity could help facilitate development of novel
therapeutic strategies to ameliorate the neurodegenerative consequences of rmTBI or
the potential triggering of AD pathogenesis by rmTBI.
Keywords: mild traumatic brain injury, Alzheimer’s disease, preclinical models, lipidomics, brain phospholipids,
sphingomyelin, omega-3 fatty acid, omega-6 fatty acid
INTRODUCTION
For many years it has been known that a history of repetitive
mild TBI (r-mTBI) increases the risk for the development of
neurodegenerative diseases such as Alzheimer’s Disease (AD)
(Gedye et al., 1989; Mortimer et al., 1991; Schofield et al., 1997;
Fleminger et al., 2003; Omalu et al., 2011; McKee et al., 2013;
Smith et al., 2013). Though the existence of this association is
very well recognized, including the shared commonalities and
distinctions between neuropathological features of TBI and AD,
have long been the topic of literature reports and discussion
(Gedye et al., 1989; Mortimer et al., 1991; Schofield et al., 1997;
Fleminger et al., 2003; Lehman et al., 2012), the precise nature
of how TBI leads to or precipitates the pathogenesis AD remains
elusive. In addition, a comprehensive well-characterized timeline
of molecular and pathogenic events following r-mTBI and in the
pathogenesis of AD has not been studied.
Lipidomic profiling is a unique tool which enables the
large-scale comprehensive analysis of novel pathways and
(patho)biological networks of lipids in the CNS. The brain is
one of the organs richest in lipid content and most particularly
phospholipids (PL) are essential components of neuronal and
non-neuronal cells in the brain. They have an integral role in
the formation of membrane lipid bilayers providing structural
integrity for protein function (Adibhatla and Hatcher, 2007).
They can also serve as precursors for various secondary
messengers that mediate signal transduction (Wenk, 2010). Fatty
acids (FA) derived from PL can also be utilized as bioenergetic
reservoirs, which are vital for metabolic support of neuronal
function (Adibhatla and Hatcher, 2007; Wenk, 2010). Imbalances
in coordination of lipid metabolism, signaling and transport,
resulting in diverse phenotypes and disease states, have been well
documented in several neurological and psychiatric conditions
(Kosicek and Hecimovic, 2013). In AD, some studies have shown
dramatic changes in PL levels such as choline plasmalogen,
phosphatidylinositiol (PI) and phosphatidylethanolamine (PE),
compared to age-matched controls (Stokes and Hawthorne,
1987; Nitsch et al., 1992; Prasad et al., 1998; Goodenowe et al.,
2007; Igarashi et al., 2011). However, most of these findings
are based on end stage AD pathology from postmortem brains.
There has also been little exploration of the trajectory of
lipid changes following r-mTBI in humans; to our knowledge
no studies have been conducted on postmortem mTBI brains
and most studies to date have been based on CSF samples
collected from severe TBI patients, which show an increase in
lipoprotein PL fractions and increased free fatty acids (FFA)
within 48 days to 1 week after injury (Pilitsis et al., 2003;
Pasvogel et al., 2010; Hankin et al., 2011). Although some of
these human studies have been insightful in providing a common
dysregulation of lipid involvement in TBI and AD, a prospective
study examining longitudinal changes is non-existent. Moreover,
the confounding heterogeneity inherent in any research of
human populations, particularly the heterogeneity of etiology of
human TBI can make it difficult to interpret findings derived
from human studies. We propose that longitudinal studies
in relevant preclinical models can assist our understanding,
and so we have applied lipidomic profiling to our preclinical
model of r-mTBI and an established model of AD (PSAPP).
We previously described the behavioral and histopathological
profiles in our established mouse model of r-mTBI from 24 h
to 24 months post-injury. Compared to sham animals, injured
animals demonstrate persistent deficits in spatial memory, white
matter damage typified by corpus callosum thinning, axonal
injury and gliosis (Mouzon et al., 2012, 2014, 2018). The
[PS1(M146L), APP(K670N, M671L)] or PSAPP mouse model
primarily represents amyloid-based pathology (Holcomb et al.,
1998). This is a very well characterized model of AD that exhibits
progressive age-dependent development of amyloid pathology
and behavioral deficits in an accelerated manner (Holcomb et al.,
1998; Wengenack et al., 2000; Sadowski et al., 2004; Trinchese
et al., 2004). To explore the interrelationship between TBI and
AD we analyzed timepoints post-TBI ranging from acute to
chronic (24 h, 3, 6, 9, and 12 months) following injury at early
adulthood (2–3 months) and in the PSAPP model we analyzed
time points encompassing ‘pre,’ ‘peri’ and ‘post’ onset of amyloid
pathology (3, 9, 15 months of age).
MATERIALS AND METHODS
Animals
PSAPP mice expressing the PS1(M146L) mutation and the
“Swedish” APP(K670N/M671L) mutation were bred in our
vivarium facility on a C57BL/6 background; wild-type littermate
controls were used as controls for PSAPP mice. C57BL/6 mice
were acquired from Jackson Laboratories, Bar Harbor, ME,
United States for breeding and for the r-mTBI/r-sham studies.
Only male mice were analyzed in this study and they were
randomly assigned to an N of 4 per group. PSAPP mice and their
C57BL/6 littermate controls were allowed to age until euthanasia
at 3, 9, and 15 months of age. Animals used for the mTBI study
were 12 weeks old at the time of injury or sham injury. Mice
were housed in standard cages under a 12 h (light vs. dark)
schedule at ambient temperature monitored between 22◦ and
23◦C. Animals were under specific pathogen free conditions.
Animals were fed food and giving water ad libitum in their cages,
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veterinary supervision was maintained in the duration of the
whole study. We did not observe any evidence of disease in the
colonies used in this study. All experiments were approved by the
Roskamp Institute Institutional Animal Care and Use Committee
on protocol - R054. Studies were performed in accordance with
Office of Laboratory Animal Welfare and National Institutes of
Health guidelines.
Experimental Closed Head Injury
The experimental closed head (mild-TBI) injury procedure was
performed as we have previously described (Mouzon et al., 2012).
Mice were anesthetized for 3 min with 1.5 L/min of oxygen
and 3% isoflurane. Following shaving of the hair above the
impact site, mice were placed in a stereotaxic frame (Just For
Mice Stereotaxic, Stoelting, Wood Dale, IL, United States) fitted
with an electromagnetic controlled impact device (Impact One
Stereotaxic Motorized Impactor, Richmond, IL, United States).
Mouse head was fixed and positioned in the stereotactic device
to prevent lateral movement as the injury was administered.
Body temperature was maintained at 37◦C on a heating pad.
Once positioned a 5-mm flat tip metal impactor attached to
the electromagnetic motorized device was zeroed on the shaved
and stretched scalp, directly above the midsagittal suture, and
tip retracted to desired depth (1 mm) prior to the delivery of
the impact using the NeuroLab controlled device (at 5 m/s and
200 ms dwell time). Animals in the TBI group received 5 TBI
injuries (or sham-injury anesthesia) over a period of 9 days with
an inter-injury interval of 48 h. Mice were made to recover on
a heating pad (set to 37◦C). This injury is sublethal and does
not cause skull fracture, subdural hemorrhage or cortical damage.
Animals become ambulatory after injuries and are monitored for
any behavioral abnormalities.
Lipidomic Analyses
Anesthetized animals at euthanasia were sacrificed by cardiac
puncture, and perfused transcardially with phosphate buffer
saline solution. Brain tissue was removed and hippocampi and
cortices dissected. Cortices were homogenized in LC/MS grade
water in a volume of 2.5× wet weight. Fifty microliter aliquots
were stored specifically for lipidomic analysis. We followed the
same methods previously described by our group (Emmerich
et al., 2017). Briefly, the Folch method (Folch et al., 1957)
was utilized to extract lipids from brain tissue spiked with
synthetic internal standards (di-14:0 FA containing PC and
PE, 14:0 FA containing (LPE) and (LPC), d18:1/17:0 SM, and
di-16:0 for PI).
Lipid extracts were resuspended in isopropanol and separation
was achieved by hydrophilic interaction chromatography on
a 1 mm × 100 mm column packed with 3 µm Pinnacle II
silica particles. We performed an isocratic run with 70% solvent
A (100% acetonitrile) in 30% solvent B (78% methanol, 1%
formic acid, 0.6% ammonium hydroxide) for a period of 15 min,
using a flow rate of 55 µl/min, and column conditions set
at 40◦C. Thermo LTQ-XL linear ion trap mass spectrometer
fitted with a Surveyor HPLC pumping system and Micro AS
autosampler (Thermo-Fisher, Waltham, MA, United States) was
used to perform mass spectrometry. In-source collision induced
dissociation (SCID), with relative energies at 15%, was used to
acquire full scan negative ion mass spectra from m/z 200–2,000.
We obtained all generated spectra with a 200 ms maximum
ion time window and by summing together 5 microscans. Mass
spectra were summed over the chromatographic peak observed
for each PL class and their spectra (each as a list of m/z
vs. intensity) and subsequently exported to Excel. Generated
excel files were subsequently uploaded to LipidomeDB for
identification and quantification of each phospholipid species
using the respective internal standard as a reference for each class.
The mass of identified lipids species and the abundance of their
isotopic variants was determined using the relevant chemical
formula - tallying the masses of [M+CHO2] ions - as we have
described in detail (see Emmerich et al., 2017). We utilized an
independent internal reference (from one naïve mouse brain)
sample to each run to control for run-to-run variability during
batch processing of TBI or AD samples. All TBI samples were
run together as a single batch experiment to allow all respective
controls and time points to be captured in our analyses. Likewise,
AD samples were also run separately with their relevant controls
and age groups. All samples were run as triplicates. All molecular
species identified within each phospholipid species class was
summed to deduce total concentrations of PC, PE, PI, and
SM species. Each phospholipid class was subsequently grouped
based on their number of double bonds as an indirect measure
of the degree of saturation as we have previously described
(Emmerich et al., 2017).
Briefly, for each phospholipid class, we determined if their
fatty acid chains contained no double bonds [as a semi-
quantitative measure or indicator of saturated fatty acid (SFA)
content]; if the total number of double bonds in the fatty
acid chains was one [a likely indicator of monounsaturated
fatty acid (MUFA) content]. Given the difficulty in determining
polyunsaturated fatty acids (PUFA) containing PLs without
additional fragmentation, we were unable to reliably determine
their levels for the respective PLs analyzed. However, we have
included a third group of classification (i.e., if the total number
of double bonds in fatty acid chains were 3 or more), where
PUFA containing species will be likely present. The authors
acknowledge that this classification is not a definitive absolute
measure of the degree of unsaturation and do not represent all
SFA, MUFA and PUFA containing lipids in our samples, but
an indirect measure of a significant pool. Phospholipid species
containing two double bonds were excluded from these analyses
given the ambiguity of double-bond position where these PL
species could represent those with either two double bonds in one
of fatty acid side chains or one double-bond in each fatty acid
side chain. We also separately grouped arachidonic acid (AA)
containing phospholipid species to docosahexaenoic acid (DHA)
containing phospholipid species, and also ether (epE, ePC) and
Lyso (LPE, LPC) containing phospholipid as we have described
elsewhere (Emmerich et al., 2017).
Statistical Plan
We determined differences in TBI or AD groups using ANOVA
or χ2 test. Samples were log transformed when parametric
assumptions were not met following tests for normality. In cases
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when transformation was unsatisfactory, non-parametric testing
was used for analyses. We performed Principal Component
Analysis (PCA) to minimize multicollinearity and to thus achieve
dimension reduction for individual species relevant to each
phospholipid (see Supplementary Tables T1–T19 for individual
species of each phospholipid), as we have previously described for
the analyses of our lipidomic datasets (Abdullah et al., 2012, 2013,
2014). Lipid species of interest were analyzed by mixed linear
modeling (MLM) regression analysis to identify lipids specifically
altered by the study treatment. Prior to performing MLM
regression analysis on each relevant component of interest (i.e.,
our outcome measure), we used the Anderson-Rubin method
to export uncorrelated scores, whilst adjusting for random
(i.e., human) factors, and to assess independent (i.e., diagnostic
and replicative) fixed factors. Following analyses using MLM,
Fischer’s least significant difference (LSD) correction and the
Benjamini–Hochberg (B-H) procedure were used for multiple-
test correction, and control of the false discovery rate (set at
0.01) for all comparisons. Analyses was conducted using SPSS
version 17 (IBM corporation) and type I error was controlled by
setting a at 0.05.
RESULTS
Phospholipid Changes in the
Hippocampi of r-mTBI and AD Animal
Models
Total Phospholipid (PE, PC, PI, and SM) Levels in the
Hippocampi of r-mTBI and PSAPP Mice
Hippocampus is a region that demonstrates significant
pathobiological changes in both TBI and AD pathogenesis.
We therefore analyzed different total phospholipid
species in this brain region of our mouse models. Total
phosphatidylethanolamine (PE), phosphatidylcholine (PC)
and sphingomyelin (SM) were significantly increased in
the hippocampi at 24 h, 6 and 12 months post-injury in
r-mTBI mice compared to shams (Table 1 and Supplementary
Figures S1A,C,F). Total phosphatidylinositol (PI) levels
were increased at 24 h and 12 months post-injury time
points (Table 1 and Supplementary Figure S1E) compared
to sham counterparts.
In WT vs. PSAPP mice, there was no change in total PE,
PC or PI at any of the time points examined (Table 1 and
Supplementary Figures S2A,C,E). Total SM was significantly
increased at 3 and 9 months of age in PSAPP compared to WT
mice (Table 1 and Supplementary Figure S2F).
Total Lyso-Phospholipid Species (LPE and LPC)
Levels in the Hippocampi of r-mTBI and PSAPP Mice
Given the changes observed in both PE and PC species, we
therefore proceeded to analyze the (Lyso) derivatives of total
PE and PC in the hippocampi of our TBI and AD mouse
models. Similar to changes observed above for total PE, total
lysophosphatidylethanolamine (LPE) was also increased at the
same timepoints at 3, 6, and 12 months post-injury compared TA
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to sham mice (Table 1 and Supplementary Figure S1B). Total
phosphatidylcholine (LPC) levels were however only increased at
24 h post-injury (Table 1 and Supplementary Figure S1D) in TBI
mice compared to sham counterparts.
In WT vs. PSAPP mice, there was no change in total LPE
at any of the time points examined between (Table 1 and
Supplementary Figure S2B), however total LPC levels was
significantly increased at 3 months of age in PSAPP vs. WT mice
(Table 1 and Supplementary Figure S2D), corresponding with
the same changes observed in TBI mice at 24 h post-injury (i.e.,
3 months of age at euthanasia).
Total Ether Phospholipid Species (ePE and ePC)
Levels in the Hippocampi of r-mTBI and PSAPP Mice
Ether-phospholipids are also an important and physiologically
relevant phospholipid species derived from total PE and PC
species analyzed above. Here we also analyzed their levels
in the hippocampi of both mouse models, and observed
a significant increase in total ether-phosphatidylethanolamine
(ePE) at 24 h, 6 and 12 months post-injury in r-mTBI mice
vs. shams (Table 1 and Supplementary Figure S3A). Total
ether-phosphatidylcholine (ePC) was significantly increased,
only at 6 months post-injury time point in r-mTBI vs. sham
mice (Table 1 and Supplementary Figure S3C). Unlike the
changes observed in TBI mice, no changes was observed
for ePE (Supplementary Figure S3B) or ePC (Table 1 and
Supplementary Figure S3D) in PSAPP vs. WT mice at any of
the age’s examined.
Arachidonic Acid (AA)- and Docosahexaenoic Acid
(DHA)- Containing Phospholipid Species, and Their
Ratio in the Hippocampi of r-mTBI and PSAPP Mice
Arachidonic acid (AA) and docosahexaenoic acid (DHA) are
polyunsaturated fatty acids, with prominent pro-inflammatory
and anti-inflammatory potential in the brain milieu, respectively.
We thus analyzed the levels of AA to DHA containing
phospholipid species (namely PE, PC, LPC, and PI) and
their relative ratio in both of our models. We observed a
significant increase in hippocampal AA levels for PC, PE, and
PI species at 24 h and 12 months post-injury time points
in r-mTBI vs. sham mice (Supplementary Figures S4A,C,E).
AA levels for LPC were significantly increased at 24 h
(Supplementary Figure S4G). Intriguingly, no change was
observed for AA levels for PC, PE and PI species in PSAPP
mice (Supplementary Figures S4B,D,E). However, there was a
significant increase in AA levels for LPC at 3 months of age,
and a surprisingly a significant decrease at 9 months of age
(Supplementary Figure S4H).
Hippocampal DHA levels were significantly increased for PC
at 24 h and 12 months post-injury, for PE species at 24 h, 6 and
12 months post-injury, for PI species at 12 months post-injury,
and for LPC at 24hrs post-injury vs. sham mice (Supplementary
Figures S4A,C,E,G). No change was observed for DHA levels
for PC, PE, PI and LPC species in PSAPP mice at any age
(Supplementary Figures S4B,D,F,H).
When we presented these changes as a ratio of AA to
DHA for the different phospholipid species, no change was
observed in the AA to DHA ratio for PC species following
r-mTBI (Supplementary Figure S5A). However, we observed a
significant increase in the AA to DHA ratio for PE, PI and LPC
species at 24 h post-injury time points in r-mTBI vs. sham mice
(Supplementary Figures S5C,E,G).
In WT vs. PSAPP mice, we observed a significant increase
in the AA to DHA ratio for PC species at 9 of age (Table 1
and Supplementary Figure S5C), while AA to DHA ratio for
PE species was significantly increased at 3, 9, and 15 months of
age compared to littermate controls (Table 1 and Supplementary
Figure S5D). No change was observed in the AA to DHA levels
for PI and LPC species in PSAPP vs. sham mice at any age
(Table 1 and Supplementary Figures S5F,H).
Classification of Phospholipid Species Based on
Number of Double Bonds in the Hippocampi of
r-mTBI and PSAPP Mice
The degree of fatty acid (FA) saturation can influence the function
of FA in a variety of ways, thus we proceeded to interrogate
phospholipid species with 0 double bonds (indicator of a pool
of SFA containing PLs), 1 double bond (indicator of a pool of
MUFA containing PLs), and 3 or more double bonds (indicator
of a likely pool of PUFA containing PLs) in the hippocampi of our
mouse models.
PC, SM, PE, and PI species with 1 double bond were
significantly increased at 24 h and 12 months post-injury; SM and
PE species with 1 double bond were also increased at 6 months
post-injury in r-mTBI compared to sham mice (Table 2). No
changes were observed for PC, SM, PE, and PI species with 1
double bond in the PSAPP group compared to littermate controls
at all ages examined (Table 3).
PC, PE, and PI species with 3 or more double bonds were
significantly increased at 24 h and 12 months post-injury, and
PC and PE species with 3 or more double bonds were also
increased at 6 months post-injury in repetitive mTBI compared
to sham mice (Table 2). No changes were observed for PC,
SM, PE, and PI species with 3 or more double bonds in
the PSAPP group compared to littermate controls at all ages
examined (Table 3).
PC, SM, and PE species with 0 double bond were significantly
increased at 24 h post-injury; PE species with 0 double bond
were significantly increased at 6 months post-injury; SM, PE
and PI species with 0 double bond were significantly increased
at 12 months post-injury in r-mTBI compared to sham mice
(Table 2). SM species with 0 double bond were significantly
increased in the PSAPP group at 3 and 9 months of age compared
to age matched WT mice (Table 3).
See Supplementary Tables T1–T8 for changes in
individual molecular species in the hippocampi for each
phospholipid class in both r-mTBI and PSAPP models. Absolute
concentrations values of the phospholipid species are presented
in Supplementary Figures S1–S5.
Phospholipid Changes in the Cortices of
r-mTBI and AD Animal Models
We conducted similar experiments described above, on
cortical tissue from our mouse model, at similar time points
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post-injury and age, focusing also on total phospholipid
species, their lyso and ether derivatives, levels of AA to DHA
containing phospholipids and their corresponding ratio, and
degree of fatty acid saturation for the different phospholipids
species analyzed.
Total Phospholipid (PE, PC, PI, and SM) Levels in the
Cortices of r-mTBI and PSAPP Mice
No changes were observed in cortical total PE or SM
in r-mTBI vs. sham mice (Table 4 and Supplementary
Figures S6A,F). Total PC levels were significantly increased
at 24 h and 12 months post-injury compared to sham
counterparts (Table 4 and Supplementary Figure S6C).
Total PI levels were significantly increased at 3 and
12 months post-injury compared to sham mice (Table 4
and Supplementary Figure S6E).
Diverging effects were observed in the WT vs. PSAPP study,
total PE, PC, and SM levels were significantly decreased at
15 months of age (Table 4 and Supplementary Figures S7A,C,F).
Total PI levels were significantly decreased at 9 and also
15 months of age in PSAPP compared to littermate controls
(Table 4 and Supplementary Figure S7E).
Total Lyso-Phospholipid Species (LPE and LPC)
Levels in the Cortices of r-mTBI and PSAPP Mice
Total LPE levels were significantly increased at 24 h, 3 and
12 months post-injury compared to sham controls (Table 4
and Supplementary Figure S6B). However, no changes were
observed in cortical total LPC in r-mTBI mice (Table 4 and
Supplementary Figure S6D ).
In the WT vs. PSAPP experimental, total LPE levels were
significantly increased at 3 months and decreased at 9 months
of age in PSAPP compared to littermate controls (Table 4
and Supplementary Figure S7B). However, total LPC was
significantly decreased at 9 months of age in PSAPP compared
to littermate controls (Table 4 and Supplementary Figure S7D).
Total etherPE and etherPC Levels in the Cortices of
Repetitive-mTBI and PSAPP Mice
There was no significant change in ether-
phosphatidylethanolamine (ePE) in r-mTBI compared to
sham mice at any of the time points examined (Table 4 and
Supplementary Figure S8A). We did observe an increase in
total ether-phosphatidylcholine (ePC) at 24 h and 12 months
post-injury in r-mTBI compared to sham mice (Table 4 and
Supplementary Figure S8C). In PSAPP mice, total cortical
epE and ePC levels showed differential effects, significantly
decreasing at 15 months of age compared to littermate controls
(Table 4 and Supplementary Figures S8B,D).
Arachidonic Acid and Docosahexaenoic Acid
Containing Phospholipid Species, and Their Ratio in
the Cortices of Repetitive mTBI and PSAPP Mice
A significant increase in cortical AA levels was observed for PC
at 24 h and 12 months post-injury, and for PI species there
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TABLE 3 | Classification of phospholipid species based on the number of double bonds (degree of fatty acid saturation) in the hippocampus of PSAPP mice.
3 months 9 months 15 months
C57BL6 PSAPP C57BL6 PSAPP C57BL6 PSAPP
Phospholipid species with 1 double bond [MUFA containing PLs] (µmol ± SEM)
PC 48.42 ± 4.72 59.08 ± 4.91 49.15 ± 4.91 55.6 ± 4.96 49.49 ± 2.39 49.24 ± 1.76
SM 2.77 ± 0.06 4.02 ± 0.57 4.3 ± 0.23 4.54 ± 0.18 4.56 ± 0.36 3.86 ± 0.32
PE 12.19 ± 0.24 15.05 ± 1.9 13.29 ± 0.81 15.21 ± 0.58 15.05 ± 1.23 14.29 ± 1.38
PI 6.94 ± 1.66 6.75 ± 1.45 6.52 ± 1.43 7.33 ± 1.59 6.22 ± 1.28 5.83 ± 1.25
Phospholipid species with 3 or more double bonds [PUFA containing PLs] (µmol ± SEM)
PC 34.94 ± 3.77 43.65 ± 3.81 34.42 ± 3.67 40.35 ± 4.04 34.44 ± 1.97 34.97 ± 1.44
PE 108 ± 3.46 134.1 ± 16.59 114.07 ± 7.48 131.55 ± 6.13 128.48 ± 11.28 118.92 ± 12.49
PI 73.73 ± 5.32 85.31 ± 6.31 81.47 ± 6.54 95.72 ± 7.43 85.52 ± 4.07 82.63 ± 4.38
Phospholipid species with 0 double bond [SFA containing PLs] (µmol ± SEM)
PC 33.58 ± 2.9 39.65 ± 3.06 32.68 ± 2.78 36.83 ± 3.37 32.25 ± 1.55 30.5 ± 0.98
SM 24.18 ± 0.69 29.74 ± 3.21∗∗∗ 26.56 ± 1.15 32.24 ± 1.08∗∗∗ 29.73 ± 1.43 28.73 ± 1.88
PE 26.05 ± 1.06 30.94 ± 3.83 25.22 ± 1.67 27.7 ± 1.18 27.22 ± 2.44 23.72 ± 2.54
PI 3.78 ± 1.1 3.42 ± 0.97 4 ± 1.08 4.86 ± 1.33 4.6 ± 1.26 4.31 ± 1.19
Significant changes in PC, SM, PE, and PI species with ‘0’, ‘1,’ or ‘3 or more’ double bonds in the hippocampus of an AD mouse model. Sample size for all groups across
all time points is n = 4. All data represents mean µM per (5.5 mg) wet weight ± SEM. Individual molecular lipid species were quantified by LC/MS and were summed
after LipidomeDB analyses to generate degree of fatty acid classification for each phospholipid species. Blue color code indicates an increase in lipid species. Asterisks
represents ∗∗∗P < 0.001 for comparisons between PSAPP/WT mice. PE, Phosphatidylethanolamine; LPE, Lysophosphatidylethanolamine; PC, Phosphatidylcholine; LPC,
Lysophosphatidylcholine; PI, Phosphatidylinositol; SM, Sphingomyelin.
was a significant decrease at 3 months post-injury followed by
a significant increase at 12 months post-injury (Supplementary
Figures S9C,E). No change was observed in AA levels for
PE and LPC species at any of the time point examined post-
injury (Supplementary Figures S9A,G). In the PSAPP model we
observed a significant decrease at 9 and 15 months of age in AA
levels for PI species (Supplementary Figure S9F). No change
was observed in AA levels for PE, PC or LPC species at any age
(Supplementary Figures S9B,D,H).
There was a significant increase in cortical DHA levels for
PC at 24 h and 12 months post-injury in r-mTBI vs. sham
mice (Supplementary Figure S9C). No significant changes
were observed in DHA levels for PE, PI or LPC species
in the r-mTBI/sham at any of the time points examined
(Supplementary Figures S9A,E,G). In the PSAPP model there
was a significant decrease in DHA levels for LPC species at
9 months of age compared to littermate controls (Supplementary
Figure S9H). No changes were observed in DHA levels for
PE, PC or PI in the PSAPP model at any age (Supplementary
Figures S9B,D,F).
AA to DHA ratio for PE and PC species showed a
significant increase at 3 and 6 months post-injury in r-mTBI
compared to sham mice (Table 4 and Supplementary
Figures S10A,C). However, no change was observed in
the AA to DHA ratio for PE and PC in the PSAPP group
compared to littermate controls at any age (Table 4 and
Supplementary Figures S10B,D).
In both r-mTBI and PSAPP models there was no
change in the AA to DHA ratio for PI species at any of
the time points examined (Table 4 and Supplementary
Figures S10E,F). For LPC species the AA to DHA
ratio was unchanged in the r-mTBI model at all time
points (Table 4 and Supplementary Figure S10G), while
there was a significant increase in PSAPP compared to
littermate controls at 9 months of age only (Table 4 and
Supplementary Figure S10H).
Classification of Phospholipid Species Based on
Number of Double Bonds in the Cortices of r-mTBI
and PSAPP Mice
PC species with 1 double bond were significantly increased
at 24 h and 12 months post-injury, PI species with 1 double
bond were increased only at 12 months post-injury in r-mTBI
compared to sham mice, and SM species with 1 double bond
were significantly decreased at 3 months post-injury (Table 3).
In the PSAPP vs. WT study, PI species with 1 double bond
were decreased at 9 months of age (Table 5). PC, SM, PE and
PI species with 1 double bond were all decreased at 15 months
of age in the PSAPP group compared to age matched littermate
controls (Table 6).
PC species with 3 or more double bonds were significantly
increased at 24 h and 12 months post-injury, but decreased at
3 months and increased at 12 months post-injury for PI in r-mTBI
compared to sham mice (Table 5). PC species with 3 or more
double bonds were decreased at 15 months of age, with this class
of phospholipids for PI also decreased at 9 and 15 months of
age in the PSAPP group compared to age matched littermate
controls (Table 6).
PC species with 0 double bond were significantly increased
at 24 h and 12 months post-injury in r-mTBI compared
to sham mice (Table 5). While PC species with 0 double
bond were differentially decreased in the PSAPP group at
15 months of age compared to age matched littermate
controls (Table 6).
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See Supplementary Tables T9–T15 for changes in individual
molecular species in the cortex for each phospholipid class in
both r-mTBI and PSAPP models. Absolute concentrations
values of the phospholipid species are presented in
Supplementary Figures S6–S10.
DISCUSSION
At the outset of this project we designed a longitudinal study
to comprehensively investigate changes in brain phospholipid
profiles in TBI (24 h to 12 months post-injury) and AD (3–
15 months of age) mouse models. Our hypothesis was that a
detailed lipid characterization would reveal profiles of response
to injury in our TBI model that overlap with age-dependent
changes in the AD Model and thus provide insights into the
TBI-AD relationship. We interrogated the hippocampus and
cortex of animals, on the basis that these brain regions were
anatomical substrates for the neurobehavioral deficits observed
in our models. Our TBI model has been well characterized
up to 24 months post injury (Mouzon et al., 2012, 2014,
2018; Ojo et al., 2015). We have demonstrated progressive
deficits in hippocampal-dependent spatial learning and memory
tasks, axonal injury, gliosis, and chronic changes in dendritic
abnormalities and electron dense dark neurons in the cortex.
In the transgenic AD model (PSAPP), mice exhibit progressive
age-dependent development of amyloid pathology, astrogliosis
and microgliosis in an accelerated manner (Holcomb et al.,
1998; Wengenack et al., 2000; Sadowski et al., 2004; Trinchese
et al., 2004), and this correlates with progressive age-related
deterioration in spatial learning and working memory tasks at
chronic stages (>15 months) compared to younger mice aged
5–7 months (Holcomb et al., 1999).
Changes in PC, PE, and PI Phospholipid
Species and Their Derivatives in the
Neurodegenerative Sequelae of TBI and
AD Pathogenesis
Our lipidomic analyses focused on six phospholipid species:
phosphatidylcholine (PC), lysoPC (LPC), phosphatidylinositol
(PI), phosphatidylethanolamine (PE), lysoPE (LPE), and
sphingomyelin (SM). There was a significant overlap in
very few brain lipid profiles in both TBI and AD models,
notable and distinct differences unique to each model were
mainly observed (see Tables 1, 2). We report a significant
increase in PC, PE (ether-PE) and PI levels at acute (24 h)
and chronic (6–12 months) time points post-injury in r-mTBI
animals within the hippocampus. In the PSAPP model we
observed no significant changes in these phospholipid species
at any of the time points we examined. In the cortex, PC
and PI species were significantly increased at both acute
and subacute (3 months) or chronic time points post-
injury following r-mTBI, whereas in the PSAPP model we
observed a reduction in the levels of PC, PI and ether-PE at 9
and/or 15 months of age, post-onset of amyloidopathy. These
findings demonstrate distinct differences in TBI and AD total
phospholipid profiles, and specific brain regional responses to
phospholipid metabolism.
A review of the literature reveals that, where lipid analyses
have been carried out in human TBI cases, changes similar
to those found in our current study have been reported.
An immediate and significant increase in total phospholipid
(PL) levels in CSF lipoprotein fractions from patients exposed
to severe TBI was significantly correlated with neurological
outcome and survival (Kay et al., 2003). In animal models
of severe TBI, similar outcomes have also been demonstrated.
We previously showed an increase in PC, PE and PI in the
hippocampus at 3 months following a controlled cortical impact
(CCI) injury (Abdullah et al., 2014). Other investigators have also
shown early (after 4 days) elevations in phospholipid metabolites
in the cortices of injured compared to control rats immediately
following severe TBI (Homayoun et al., 1997). Our study is the
only one to report longitudinal changes up to 1-year post-injury
in a mouse model of r-mTBI, and we show that the immediate
changes in phospholipids do not completely resolve and appear
exacerbated at chronic time points post-injury. Such changes
in PL levels could implicate a dysregulation in metabolic and
catabolic processes for these lipid species, deficits in peroxisomal
function involved in phospholipid synthesis, or a possible failure
of abluminal lipid eﬄux transporters. In human AD cases,
phospholipid levels have been previously reported to dramatically
change compared to age matched controls. Significant reductions
in levels of PI (68%) and PE (15%) have been reported in post-
mortem (gray matter) tissue in AD compared to controls (Stokes
and Hawthorne, 1987; Nitsch et al., 1992; Prasad et al., 1998)
and also in our MCI/AD cases (Abdullah et al., 2017, Personal
communication). Increased PL hydrolysis has been suggested
as an underlying mechanism for reduced levels of PL in AD
brain tissue. This is evidenced by the increase in phospholipid
(PC) metabolites observed in the CSF of AD patients (Mulder
et al., 2003; Walter et al., 2004). In line with these data we
observed an increase in lysoPC and lysoPE (both indicative
of PL metabolism) in the hippocampus and/or cortex at 3
or 9 months of age in the PSAPP model, and a reduction
in PL levels in the cortex. However, there was an intriguing
lack of change in the hippocampus. The consequences of PL
reduction may have serious effects on the integrity of neurons,
glia and cerebrovascular cell functions, and may contribute
to the pathogenesis of AD, especially since PL play such a
significant role in regulating the behavior of membrane proteins
and enzymes involved in APP processing (Jicha and Markesbery,
2010). The reason behind the differences seen in the hippocampi
and cortices of PSAPP mice is unknown. Clearly in the PSAPP
model the emergence of mutagenic genotype driven amyloid
pathology is present early at 6 months of age in both the
hippocampus and cortex (Holcomb et al., 1998; Gordon et al.,
2002), suggesting that these brain regional lipid differences are
not directly linked to the onset of amyloidogenesis. No brain-
region specific lipidomic characterization of phospholipids has
been performed thus far in mouse models, levels of phospholipids
were typically higher in the cortex compared to the hippocampus
of our models, and as is the case in the human studies described
above, a similar pattern also emerges, with higher levels of
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TABLE 6 | Classification of phospholipid species based on the number of double bonds (degree of fatty acid saturation) in the cortex of PSAPP mice.
3 months 9 months 15 months
C57BL6 PSAPP C57BL6 PSAPP C57BL6 PSAPP
Phospholipid species with 1 double bond [MUFA containing PLs] (µmol ± SEM)
PC 118.53 ± 7.41 120.85 ± 2.53 131.53 ± 4.02 123.34 ± 3.8 119.94 ± 7.05 101.21 ± 5.45∗
SM 5.95 ± 0.18 6.53 ± 0.26 9.42 ± 0.36 8.17 ± 0.35 9.1 ± 0.47 6.82 ± 0.48∗∗∗
PE 25.94 ± 0.82 27.82 ± 0.58 32.07 ± 1.13 29.41 ± 0.92 30.31 ± 1.96 26.43 ± 1.56∗∗∗
PI 14.36 ± 0.88 12.5 ± 0.43 16.9 ± 0.86 13.60 ± 0.89∗ 13.63 ± 0.74 11.60 ± 0.51∗
Phospholipid species with 3 or more double bonds [PUFA containing PLs] (µmol ± SEM)
PC 97.5 ± 5.26 98.2 ± 2.32 101.16 ± 2.65 98.15 ± 3.73 90.14 ± 5.78 83.160∗
PE 234.29 ± 9.8 249.8 ± 8.1 284.86 ± 15.98 262.41 ± 12.01 272.92 ± 16.12 221.78 ± 12.57
PI 97.94 ± 2.77 97.79 ± 5.79 141.64 ± 7.07 115.23 ± 4.82∗∗∗ 133.55 ± 5.7 105.14 ± 6.03∗∗∗
Phospholipid species with 0 double bond [SFA containing PLs] (µmol ± SEM)
PC 88 ± 4.91 83.62 ± 2.59 92.05 ± 3.3 82.18 ± 3.01 81.57 ± 5.04 69.04 ± 3.44∗∗
SM 4.29 ± 0.19 4.52 ± 0.17 5.17 ± 0.15 5.14 ± 0.29 5.12 ± 0.25 4.37 ± 0.24
PE 57.77 ± 2.4 58.27 ± 1.35 63.19 ± 3.18 59.22 ± 1.86 58.15 ± 3.87 48.44 ± 3.82
PI 8.07 ± 0.3 7.79 ± 0.32 9.47 ± 0.42 9.18 ± 0.28 9.15 ± 0.42 8.39 ± 0.32
Significant changes in PC, SM, PE, and PI species with ‘0’, ‘1’ or ‘3 or more’ double bonds in the cortex of an AD mouse model. Sample size for all groups across
all time points is n = 4. All data represents mean µM per (10 mg) wet weight ± SEM. Individual molecular lipid species were quantified by LC/MS and were summed
after LipidomeDB analyses to generate degree of fatty acid classification for each phospholipid species. Red color code indicates a decrease in lipid species. Asterisks
represents ∗P < 0.05 (lightest shade of red); ∗∗P < 0.01 (middle shade of red); ∗∗∗P < 0.001 (darkest shade of red) for comparisons between PSAPP/WT mice. PE,
Phosphatidylethanolamine; LPE, Lysophosphatidylethanolamine; PC, Phosphatidylcholine; LPC, Lysophosphatidylcholine; PI, Phosphatidylinositol; SM, Sphingomyelin.
PLs observed in the cortex compared to the hippocampus. It
thus appears that disruption of lipid homeostasis through a
significant increase OR decrease in these lipid species could be
detrimental to brain (patho)physiology as we have observed in
our TBI and AD models. Future studies will need to explore
enzymatic hydrolysis or trafficking/transport of phospholipids in
these brain regions and how they impact on lipid pathways and
neurodegenerative processes.
Ether phospholipids, particularly plasmalogens [epE (38:6);
(40:4); (40:5); (40:6) - Supplementary Tables T2, T14, and
T16] that contain O-alk-1-enyl at the sn1 position, play a
role in cholesterol esterification, maintenance of myelin covered
axonal nodes, and vesicular formation/exocytosis (Lohner, 1996;
Gorgas et al., 2006; Mankidy et al., 2010). The increase
in hippocampal ether PE levels seen in our r-mTBI model
indicates a possible activation of reparative processes involving
attempts at remyelination of damaged or sheared axons,
and stimulation of exocytosis and neurotransmitter signaling.
Whereas, in the AD model, the reduction observed could signal a
significant breakdown in myelin integrity, saltatory conduction,
and neurotransmission. A deficiency of plasmalogen content
within phospholipids in the gray matter has been previously
highlighted as a prominent feature of AD (Han et al., 2001;
Gorgas et al., 2006). It thus appears that the opposite or
discrepant effects in the TBI model (versus AD) may be an
attempt to repair, whereas in the AD model it may signify a purely
degenerative feature.
Changes in Sphingomyelin Lipid Species
in the Neurodegenerative Sequelae of
TBI and AD Pathogenesis
We analyzed sphingomyelin levels in both models, and report a
significant increase at acute (24 h) and chronic (6–12 months)
time points in the hippocampus of injured animals, with no
appreciable changes observed in the cortex. In the PSAPP model
an increase in sphingomyelin in the hippocampus at 3 and
9 months of age, and a reduction in the cortex at 15 months of
age was observed. These findings reflect co-incidental changes
within the hippocampus in both TBI and AD models. In line
with this study, we previously showed similar trends of increased
SM in the hippocampus 3 months post-CCI (Abdullah et al.,
2014). In AD, previous studies have investigated levels of SM
with contradictory results, most reports show an increase in
SM levels in human AD gray matter and cerebellum (Pettegrew
et al., 2001; Bandaru et al., 2009), and a 50% increase in SM has
also been reported in the CSF of prodromal AD cases (Kosicek
et al., 2012). Two separate studies, however, reported a reduction
in SM levels in homogenates from the frontal and temporal
gyrus (Cutler et al., 2004; He et al., 2010). However, these latter
studies were conducted in a smaller group of individuals (7–9)
than the former studies (30–45) and therefore require further
validation. The reason behind the discrepant changes observed
in the cortex and hippocampus herein also remains unknown,
to our knowledge no human studies to date has examined
comparative levels of sphingomyelin in both brain regions in
AD cases. Several outcomes can, however, be predicted from
increases in sphingomyelin. It is associated with lipid rafts and
is expressed in the membranous myelin sheath surrounding
nerve cell axons (Kosicek and Hecimovic, 2013) thus an increase
in SM levels could have an influence on membrane sorting-
trafficking and remyelination of damaged axons which will
be anticipated as part of the repair mechanism in our TBI
model. Sphingomyelin can also be degraded by sphingomyelin
synthatase 2 into diacylglycerol that has a role in the activation
of protein kinase C, which is important for neuronal survival
and reparative mechanisms (Kosicek and Hecimovic, 2013).
Deleterious effects can also arise from the hydroxylation of
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sphingomyelin into ceramides, which is known to activate
apoptotic signaling pathways involved in neurodegeneration
(Kosicek and Hecimovic, 2013).
Changes in the Degree of Fatty Acid
Saturation of Phospholipids in the
Neurodegenerative Sequelae of TBI and
AD Pathogenesis
Degree of FA saturation can influence the function of FA in
a variety of ways and this can impact neuronal and brain
function. We classified phospholipids based on their number
of double bonds as an indicator of a potential pool of SFA
(0 double bond), MUFA (1 double bond), and PUFA (3 or
more double bonds). As indicated in our methodology we
acknowledge the limitations of this analytical approach in
classifying the degree of FA saturation, particularly for the pool of
PUFA containing PLs which require additional fragmentation to
definitively determine their structural composition and absolute
levels. Our study thus only provides a semi-quantitative measure,
and thus should be interpreted with this knowledge of our limited
analytical approach.
We found distinct patterns of changes in both r-mTBI and
AD models, including unique regional brain differences. In
the r-mTBI model levels of PC and PI fractions for all three
different classifications above were significantly increased in the
hippocampus and cortex at acute and/or chronic time points.
Hippocampal SM containing 0 and 1 double bonds (i.e., SFA
or MUFA containing) were also increased following TBI. In the
AD model, we observed no changes in any of the three different
classifications for PC and PI species in the hippocampus, but
a notable reduction in all three classes of PC fractions, and a
reduction in PE and PI fractions with 3 or more double bonds was
observed in the cortex at 9 and/or 15 months of age. SM species
with 1 double bond (i.e., MUFA containing) were reduced in the
cortex of PSAPP mice.
Brain SFA levels can be directly regulated by synthesis in
the brain or through diet and transport from the periphery.
High dietary intake of SFAs such as palmitic and stearic acid
have been associated with poor cognitive performance, and are
high-risk factors for cardiovascular and brain related disease
(Engelhart et al., 2002; Whitmer et al., 2005; Barnard et al.,
2014). SFA’s such as octanoic and Myristic acids have been
shown to cross the BBB to impact brain function (Spector,
1988a,b), contributing toward oxidative stress, inflammation, and
impaired vascularization/BBB integrity (Pallebage-Gamarallage
et al., 2010; Takechi et al., 2010a,b; Freeman and Granholm, 2012;
Hsu and Kanoski, 2014). Such deleterious effects could be the
consequences of increased SFA seen in our TBI model. In line
with our findings, elevated levels of palmitic and stearic acids
have also been reported in the brain of rats immediately following
severe TBI (Homayoun et al., 1997).
The main monounsaturated FA found in the brain is
oleic acid (Bazinet and Laye, 2014) which is present in high
levels in Mediterranean diets, and has long been associated
with protection against inflammatory and vascular pathologies
(Carrillo et al., 2012). In vivo and in vitro studies have reported
oleic acid’s ability to inhibit oxidative stress, drive polarization
of M2 macrophage/microglia, promote neurotropic support and
myelination (Medina and Tabernero, 2002; Carrillo et al., 2012).
In human studies of TBI, high levels of oleic acid have been shown
in the CSF 48 h after injury (Pilitsis et al., 2003). The elevations
in MUFA-containing phospholipids in the brain following TBI
could signal the activation of neuroprotective mechanisms,
while MUFA reductions at later stages in the AD model could
contribute to the cascade of neurodegenerative events following
amyloid deposition. In support of this observation, a transgenic
mouse model of AD [harboring the Swedish (K670N/M671L) and
Indiana (V717F) APP mutations] placed on a diet enriched with
high oleic acid levels showed neuroprotective effects typified by
reduced BACE, increased amyloid clearance enzyme (IDE) and
reduced amyloid plaques (Amtul et al., 2011).
Profiles of Omega-3 and Omega 6 Fatty
Acid Containing Levels of Phospholipids
in the Neurodegenerative Sequelae of
TBI and AD Pathogenesis
The two most predominant PUFAs in the brain are omega-
6 arachidonic acid (AA) and omega-3 docosahexaenoic acid
(DHA). AA and DHA each make up approximately 10% of the
total FA within brain phospholipids (Bazinet and Laye, 2014). In
this study we reveal a significant increase in the AA to DHA ratio
(for PE and PI fractions) in the hippocampus at the acute time
points after r-mTBI, while in the PSAPP model we observed a
significant increase at all time points for PE fractions. Within the
cortex a significant increase in AA:DHA (for PE and PC fractions)
was observed at 3 and 6 months post-injury; while in the PSAPP
model we did not observe any significant cortical changes.
The data from our r-TBI model are consistent with previously
reported TBI work from our group showing a significant
increase in brain AA:DHA in the CCI model at 3 months post-
injury (Abdullah et al., 2014). Additionally, studies in humans
examining CSF samples of patients exposed to TBI, have also
demonstrated a significant increase in AA (in its free form)
1-week after insult and this was associated with severity of
outcome using the Glasgow Outcome Scale (Pilitsis et al., 2003).
Consistently, in AD cases, decreased DHA levels in post-mortem
brains (Yuki et al., 2014) and increased blood omega-6 (relative
to omega-3) levels have also been shown to be associated with
increased cognitive decline (Conquer et al., 2000; Beydoun et al.,
2007; Cherubini et al., 2007; Heude et al., 2003; Tully et al.,
2003). In a recent study we showed that MCI/AD plasma and
cortical tissue demonstrated a significant increase in AA:DHA
ratio in different phospholipid species compared to healthy
controls (Abdullah et al., 2017, Personal communication). It is
noteworthy that our work herein has examined PE, PI, PC,
LPC for DHA and AA containing phospholipids, and we have
not explored DHA and AA containing phosphatidylserine (PS).
PS is synthetized from PC and PE, and is the major DHA
containing phospholipid in the brain (Kim et al., 2014). Thus
we acknowledge the limitations of our study, as we have only
looked at a small pool of DHA containing phospholipids in the
brain. Nonetheless, considering the consistent changes observed
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in AA/DHA ratio for four different classes of phospholipids,
and previous reports of glial activation/neuroinflammation in
our models (Mouzon et al., 2012, 2014), we anticipate that
similar changes may be observed in AA/DHA ratio for PS in
the brain regions assessed. We plan in future studies to include
DHA/AA ratio containing PS in our analyses, and to develop a
bioactive lipid assay to measure free form of DHA, AA and other
bioactive lipids.
AA and DHA are derived from long chain PUFAs.
Arachidonic acid is a precursor of eicosanoids and leukotrienes
that are main drivers of pro-inflammatory responses and vascular
permeability (Wenk, 2010; Bazinet and Laye, 2014), while
DHA, which comprises 97% of the brains omega-3 long chain
PUFAs, is a precursor for end metabolites such as resolvins
and protectins, which have a potent anti-inflammatory, anti-
oxidant, anti-apoptotic and neurotrophic effect (Adibhatla and
Hatcher, 2007; Ariel and Serhan, 2007; Bazinet and Laye, 2014).
High concentrations of DHA are found in brain regions with
high metabolic demands such as: the cortex, mitochondria
organelles, synaptosomes fractions and synaptic vesicles. An
increase in AA:DHA ratio suggests a shift toward inflammation
and vascular disruption, possibly involving increased release of
pro-inflammatory bioactive lipid metabolites (eicosanoids) and
bioactive vascular factors (leukotrienes) (Bailes and Patel, 2014).
Under such pro-inflammatory conditions, the vulnerability of
long chain PUFAs to oxidative damage could increase the
likelihood of a negative feedback on PUFAs, resulting in
lipid peroxidation and generation of free radical species and
toxic lipid byproducts such as 4-hydroxynonenal (4-HNE),
Malondialdehyde (MDA) or 8-isoprostane. We are yet to
investigate these possible outcomes in our TBI model, further
work will be required to confirm this. Blocking enzymes
such as phospholipase A2 and C involved in the conversion
of phospholipids into arachidonic acid may offer therapeutic
opportunity in TBI and AD. Moreover, supplementing DHA
levels at the appropriate therapeutic window of opportunity
could be beneficial in stimulating the brain’s DHA-dependent
neuroprotective mechanisms. Dietary DHA supplements have
been shown to alter brain phospholipid levels (Jumpsen et al.,
1997), and in animal models of TBI, prophylactic treatment
with DHA demonstrates neuroprotective outcomes (Mills et al.,
2011) improving behavioral memory, reducing axonal injury
and microglial activation (Bailes and Mills, 2010). Likewise,
mice placed on an omega-3 fatty acid deficient diet display
impaired recovery from CCI compared to omega-3 adequate
mice (Desai et al., 2014). In AD, greater dietary intake of omega-
3 fatty acids reduced amyloid plaques (Grimm et al., 2011)
and demonstrate 60% less risk of developing or progressing
to AD (Morris et al., 2003). The prospective Framingham and
Minnesota atherosclerosis studies noted protection from AD
(Schaefer et al., 2006; Beydoun et al., 2007), and less decline in
verbal fluency in patients with increased blood omega-3 fatty acid
levels (Beydoun et al., 2007). The source of essential PUFA in
the brain is primarily through diet and production in the liver,
which can then be transported to the brain through the BBB
via several routes: as FFAs bound to albumin, in esterified forms
within lipoproteins, or as lysophospholipids through transporters
such as MFSD2A. Impairment in one or more of these transport
mechanisms specific to AA or DHA PUFAs could account for the
imbalance in omega-6 to omega-3 ratio in vivo.
CONCLUSION
We have conducted a comprehensive assessment of phospholipid
profiles in TBI and AD mouse models over a longitudinal
time course. Our data indicate heterogeneous and overlapping
outcomes in both models. We observed a coincidental increase
in lysoPC and sphingomyelin levels and AA to DHA ratio in both
TBI and AD models, reflecting the ongoing neuroinflammation
and presenting one possible route by which TBI precipitates
AD pathogenesis. However, total PE/ePE, PC and PI levels
and their SFA, MUFA and potential PUFA containing species
showed a trend toward increase at acute and/or chronic time
points post-injury, while in the AD model, levels were either
unchanged or reduced at later time points of age. A caveat of
this study was the lack of direct statistical comparison between
TBI and AD models, and also the missing time points/ages
in the TBI vs. AD groups. The former was partly attributed
to the design of our lipidomic workflow experiments, whereby
we were only able to run batch samples of complete TBI
vs. respective control sham injury groups at all time points
post injury alone, or separately PSAPP vs. respective littermate
control groups at all age groups, in a single experiment. As a
result, we have conducted our statistical analyses in the same
manner focusing on TBI specific changes over the five different
time points, and also AD dependent changes over the three
different age-groups, and looking for overlaps in the trajectory of
profiles overtime.
Nonetheless, our data, still demonstrates significant
contributions of lipid dysregulation to both AD and TBI
pathogenesis, at least in these preclinical models, but the
nature of the disruption is not consistent. We suggest that
these differences to some extent derive from the progressive
decline in AD compared to the anticipated coincidence of
neurodegenerative and neuroreparative mechanisms in TBI
sequelae. Therapeutic approaches in TBI are confounded by
these sequelae and the changing nature of what to target, and
when, and our data suggest that although TBI can initiate lipid
changes which may contribute to, or even trigger, Alzheimer’s
like pathogenesis, they also indicate the existence of unique TBI
neurodegenerative mechanisms. We anticipate that this work
will initiate future studies involving further dissection of the lipid
biology (particularly downstream bioactive lipids) in TBI and
AD pathogenesis that will help to identify the reparative versus
degenerative brain responses to injury and thus enabling focused
lipid-based treatment strategies.
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FIGURE S1 | Total Phospholipid levels in the hippocampi of r-mTBI mice.
Significant changes in total phospholipid (PE, LPE, PC, LPC, PI, SM) species in
the hippocampi of a mouse model of repetitive-mTBI (A–F). N = 4 for all groups at
each time point. All data represent mean µM per (5.5 mg) wet weight ± SEM.
Individual molecular lipid species were quantified by LC/MS and were summed
after LipidomeDB analyses to generate total phospholipid levels. Asterisks
represent ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 for comparisons between
sham/r-mTBI mice. PE, Phosphatidylethanolamine; LPE,
Lysophosphatidylethanolamine; PC, Phosphatidylcholine; LPC,
Lysophosphatidylcholine; PI, Phosphatidylinositol; SM, Sphingomyelin.
FIGURE S2 | Total Phospholipid levels in the hippocampi of PSAPP mice.
Significant changes in total phospholipid (PE, LPE, PC, LPC, PI, SM) species in
the hippocampi of the PSAPP mouse model compared to littermate controls
(A–F). N = 4 for all groups at each time point. All data represents mean µM per
(5.5 mg) wet weight ± SEM. Individual molecular lipid species were quantified by
LC/MS and were summed after LipidomeDB analyses to generate total
phospholipid levels. Asterisks represent ∗∗∗P < 0.001 for comparisons between
PSAPP/WT mice. PE, Phosphatidylethanolamine; LPE,
Lysophosphatidylethanolamine; PC, Phosphatidylcholine; LPC,
Lysophosphatidylcholine; PI, Phosphatidylinositol; SM, Sphingomyelin.
FIGURE S3 | Total etherPE and ether PC levels in the hippocampus of
repetitive-mTBI and PSAPP mice. Significant changes in total etherPE and
etherPC lipid species in the hippocampus of a mouse model of repetitive-mTBI
and AD (A–D). Sample size for all groups across all time points is n = 4. All data
represents mean µM per (5.5 mg) wet weight ± SEM. Individual molecular lipid
species were quantified by LC/MS and were summed after LipidomeDB analyses
to generate total etherphospholipid levels. Asterisks represents ∗P < 0.05;
∗∗P < 0.01; ∗∗∗P < 0.001 for comparisons between sham/r-mTBI mice or
PSAPP/WT mice. ePE, etherphosphatidylethanolamine; ePC,
etherphosphatidylcholine.
FIGURE S4 | Arachidonic acid and decosahexaenoic acid containing
phospholipid species in the hippocampus of repetitive mTBI and PSAPP mice.
Significant changes in arachidonic acid and decosahexaenoic acid containing PC,
PE and PI species in the hippocampus of a mouse model of repetitive-mTBI and
AD (A–H). Sample size for all groups across all time points is n = 4. Data
represents mean µmol per wet weight (5.5 mg) ± SEM. Individual molecular lipid
species were quantified by LC/MS and were summed after LipidomeDB analyses
to generate arachidonic and decosahexaenoic acid levels for each phospholipid
species. Asterisks represents ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 for
comparisons between sham/r-mTBI mice or WT/PSAPP mice. PE,
Phosphatidylethanolamine; PC, Phosphatidylcholine; PI, Phosphatidylinositol;
LPC, Lysophosphatidylcholine; AA, arachidonic acid; DHA, decosahexaenoic acid.
FIGURE S5 | Arachidonic acid to decosahexaenoic acid ratio containing
phospholipid species in the hippocampus of repetitive mTBI and PSAPP mice.
Significant changes in arachidonic acid to decosahexaenoic acid ratio for PC, PE,
and PI phospholipid species in the hippocampus of a mouse model of
repetitive-mTBI and AD (A–H). Sample size for all groups across all time points is
n = 4. Data represents arbitrary value (ratio) value ± SEM. Individual molecular lipid
species were quantified by LC/MS and were summed after LipidomeDB analyses
to generate AA and DHA levels for each phospholipid species, and a ratio of AA to
DHA was compiled from these values. Asterisks represents ∗P < 0.05;
∗∗P < 0.01; ∗∗∗P < 0.001 for comparisons between sham/r-mTBI mice or
WT/PSAPP mice. PE, Phosphatidylethanolamine; PC, Phosphatidylcholine; PI,
Phosphatidylinositol; LPC, Lysophosphatidylcholine; AA, arachidonic acid; DHA,
decosahexaenoic acid.
FIGURE S6 | Total Phospholipid levels in the cortex of r-mTBI mice. Significant
changes in total phospholipid (PE, LPE, PC, LPC, PI, SM) species in the cortex of
a mouse model of repetitive-mTBI (A–F). Sample size for all groups across all time
points is n = 4. All data represents mean µM per (10) wet weight ± SEM.
Individual molecular lipid species were quantified by liquid chromatography/mass
spectrometry and were summed after LipidomeDB analyses to generate total
phospholipid levels. Asterisks represents ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 for
comparisons between sham/r-mTBI mice. PE, Phosphatidylethanolamine; LPE,
Lysophosphatidylethanolamine; PC, Phosphatidylcholine; LPC,
Lysophosphatidylcholine; PI, Phosphatidylinositol; SM, Sphingomyelin.
FIGURE S7 | Total Phospholipid levels in the cortex of PSAPP mice. Significant
changes in total phospholipid (PE, LPE, PC, LPC, PI, SM) species in the cortex of
a PSAPP mouse model (A–F). Sample size for all groups across all time points is
n = 4. All data represents mean µM per (10 mg) wet weight ± SEM. Individual
molecular lipid species were quantified by liquid chromatography/mass
spectrometry and were summed after LipidomeDB analyses to generate total
phospholipid levels. Asterisks represents ∗∗∗P < 0.001 for comparisons between
PSAPP/WT mice. PE, Phosphatidylethanolamine; LPE,
Lysophosphatidylethanolamine; PC, Phosphatidylcholine; LPC,
Lysophosphatidylcholine; PI, Phosphatidylinositol; SM, Sphingomyelin.
FIGURE S8 | Total etherPE and ether PC levels in the cortex of repetitive mTBI
and PSAPP mice (A–D). Significant changes in total etherPE and etherPC lipid
species in the cortex of a mouse model of repetitive-mTBI and AD. Sample size
for all groups across all time points is n = 4. All data represents mean µM per
(10 mg) wet weight ± SEM. Individual molecular lipid species were quantified by
liquid chromatography/mass spectrometry and were summed after LipidomeDB
analyses to generate total etherphospholipid levels. Asterisks represents
∗P < 0.05; ∗∗∗P < 0.001 for comparisons between sham/r-mTBI mice or
PSAPP/WT mice. ePE, etherphosphatidylethanolamine; ePC,
etherphosphatidylcholine.
FIGURE S9 | Arachidonic acid and decosahexaenoic acid containing
phospholipid species in the cortex of repetitive mTBI and PSAPP mice. Significant
changes in arachidonic acid and decosahexaenoic acid containing PC (C,D), PE
(A,B), PI (E,F), and LPC (G,H) species in the cortex of a mouse model of
repetitive-mTBI and AD. Sample size for all groups across all time points is n = 4.
Data represents mean µmol per wet weight (10 mg) ± SEM. Individual molecular
lipid species were quantified by liquid chromatography/mass spectrometry and
were summed after LipidomeDB analyses to generate arachidonic and
decosahexaenoic acid levels for each phospholipid species. Asterisks represents
∗∗P < 0.01 for comparisons between sham/r-mTBI mice or WT/PSAPP mice. PE,
Phosphatidylethanolamine; PC, Phosphatidylcholine; PI, Phosphatidylinositol;
LPC, Lysophosphatidylcholine; AA, arachidonic acid; DHA, decosahexaenoic acid.
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FIGURE S10 | Arachidonic acid to decosahexaenoic acid ratio containing
phospholipid species in the cortex of repetitive mTBI and PSAPP mice. Significant
changes in arachidonic acid to decosahexaenoic acid ratio for PC (C,D), PE
(A,B), PI (E,F), and LPC (G,H) phospholipid species in the cortex of a mouse
model of repetitive-mTBI and AD. Sample size for all groups across all time points
is n = 4. Data represents arbitrary value (ratio) value ± SEM. Individual molecular
lipid species were quantified by liquid chromatography/mass spectrometry and
were summed after LipidomeDB analyses to generate AA and DHA levels for each
phospholipid species, and a ratio of AA to DHA was compiled from these values.
Asterisks represents ∗P < 0.05; ∗∗∗P < 0.001 for comparisons between
sham/r-mTBI mice or WT/PSAPP mice. PE, Phosphatidylethanolamine; PC,
Phosphatidylcholine; PI, Phosphatidylinositol; LPC, Lysophosphatidylcholine; AA,
arachidonic acid; DHA, decosahexaenoic acid.
TABLE T1 | Phosphatidylcholine lipid species in the hippocampus of r-mTBI mice.
Significant changes in individual species containing phosphatidylcholine. Sample
size for all groups across all time points is n = 4. All data represents mean µM per
(5.5 mg) wet weight ± SEM. Individual molecular lipid species were quantified by
liquid chromatography/mass spectrometry. Highlighted boxes show significantly
regulated levels (P < 0.001) between repetitive-mTBI/sham mice based on mixed
linear modeling regression analysis.
TABLE T2 | Phosphatidylethanolamine lipid species in the hippocampus of r-mTBI
mice. Significant changes in individual species containing
phosphatidylethanolamine. Sample size for all groups across all time points is
n = 4. All data represents mean µM per (5.5 mg) wet weight ± SEM. Individual
molecular lipid species were quantified by liquid chromatography/mass
spectrometry. Highlighted boxes show significantly regulated levels (P < 0.001)
between repetitive-mTBI/sham mice based on mixed linear modeling regression
analysis.
TABLE T3 | Lysophosphatidylethanolamine lipid species in the hippocampus of
r-mTBI mice. Significant changes in individual species containing
lysophosphatidylethanolamine. Sample size for all groups across all time points is
n = 4. All data represents mean µM per (5.5 mg) wet weight ± SEM. Individual
molecular lipid species were quantified by liquid chromatography/mass
spectrometry. Highlighted boxes show significantly regulated levels (P < 0.001)
between repetitive-mTBI/sham mice based on mixed linear modeling regression
analysis.
TABLE T4 | Phosphatidylinositol lipid species in the hippocampus of r-mTBI mice.
Significant changes in individual species containing phosphatidylinositiol. Sample
size for all groups across all time points is n = 4. All data represents mean µM per
(5.5 mg) wet weight ± SEM. Individual molecular lipid species were quantified by
liquid chromatography/mass spectrometry. Highlighted boxes show significantly
regulated levels (P < 0.001) between repetitive-mTBI/sham mice based on mixed
linear modeling regression analysis.
TABLE T5 | Sphingomyelin lipid species in the hippocampus of r-mTBI mice.
Significant changes in individual species containing sphingomyelin. Sample size
for all groups across all time points is n = 4. All data represents mean µM per
(5.5 mg) wet weight ± SEM. Individual molecular lipid species were quantified by
liquid chromatography/mass spectrometry. Highlighted boxes show significantly
regulated levels (P < 0.001) between repetitive-mTBI/sham mice based on mixed
linear modeling regression analysis.
TABLE T6 | Lysophosphatidylcholine lipid species in the hippocampus of
r-mTBI mice. Significant changes in individual species containing
lysophosphatidylcholine. Sample size for all groups across all time points is n = 4.
All data represents mean µM per (5.5 mg) wet weight ± SEM. Individual molecular
lipid species were quantified by liquid chromatography/mass spectrometry.
Highlighted boxes show significantly regulated levels (P < 0.001) between
repetitive-mTBI/sham mice based on mixed linear modeling regression analysis.
TABLE T7 | Sphingomyelin lipid species in the hippocampus of PSAPP mice.
Significant changes in individual species containing sphingomyelin. Sample size
for all groups across all time points is n = 4. All data represents mean µM per
(5.5 mg) wet weight ± SEM. Individual molecular lipid species were quantified by
liquid chromatography/mass spectrometry. Highlighted boxes show significantly
regulated levels (P < 0.001) between PSAPP/WT mice based on mixed linear
modeling regression analysis.
TABLE T8 | Lysophosphatidylcholine lipid species in the hippocampus of PSAPP
mice. Significant changes in individual species containing lysophosphatidylcholine.
Sample size for all groups across all time points is n = 4. All data represents mean
µM per (5.5 mg) wet weight ± SEM. Individual molecular lipid species were
quantified by liquid chromatography/mass spectrometry. Highlighted boxes show
significantly regulated levels (P < 0.001) between PSAPP/WT mice based on
mixed linear modeling regression analysis.
TABLE T9 | Phosphatidylcholine lipid species in the cortex of r-mTBI mice.
Significant changes in individual species containing phosphatidylcholine. Sample
size for all groups across all time points is n = 4. All data represents mean µM per
(10 mg) wet weight ± SEM. Individual molecular lipid species were quantified by
liquid chromatography/mass spectrometry. Highlighted boxes show significantly
regulated levels (P < 0.001) between repetitive-mTBI/sham mice based on mixed
linear modeling regression analysis.
TABLE T10 | Lysophosphatidylethanolamine lipid species in the cortex of r-mTBI
mice. Significant changes in individual species containing
lysophosphatidylethanolamine. Sample size for all groups across all time points is
n = 4. All data represents mean µM per (10 mg) wet weight ± SEM. Individual
molecular lipid species were quantified by liquid chromatography/mass
spectrometry. Highlighted boxes show significantly regulated levels (P < 0.001)
between repetitive-mTB/sham mice based on mixed linear modeling regression
analysis.
TABLE T11 | Phosphatidylinositol lipid species in the cortex of r-mTBI mice.
Significant changes in individual species containing phosphatidylinositol. Sample
size for all groups across all time points is n = 4. All data represents mean µM per
(10 mg) wet weight ± SEM. Individual molecular lipid species were quantified by
liquid chromatography/mass spectrometry. Highlighted boxes show significantly
regulated levels (P < 0.001) between repetitive-mTBI/sham mice based on mixed
linear modeling regression analysis.
TABLE T12 | Sphingomyelin lipid species in the cortex of r-mTBI mice. Significant
changes in individual species containing sphingomyelin. Sample size for all groups
across all time points is n = 4. All data represents mean µM per (10 mg) wet
weight ± SEM. Individual molecular lipid species were quantified by liquid
chromatography/mass spectrometry. Highlighted boxes show significantly
regulated levels (P < 0.001) between repetitive-mTBI/sham mice based on mixed
linear modeling regression analysis.
TABLE T13 | Lysophosphatidycholine lipid species in the cortex of r-mTBI mice.
Significant changes in individual species containing lysophosphatidylcholine.
Sample size for all groups across all time points is n = 4. All data represents
mean µM per (10 mg) wet weight ± SEM. Individual molecular lipid
species were quantified by liquid chromatography/mass spectrometry.
Highlighted boxes show significantly regulated levels (P < 0.001) between
repetitive-mTBI/sham mice based on mixed linear modeling regression
analysis.
TABLE T14 | Phosphatidylethanolamine lipid in the cortex of PSAPP mice.
Significant changes in individual species containing phosphatidylethanolamine.
Sample size for all groups across all time points is n = 4. All data represents mean
µM per (10 mg) wet weight ± SEM. Individual molecular lipid species were
quantified by liquid chromatography/mass spectrometry. Highlighted boxes show
significantly regulated levels (P < 0.001) between PSAPP/WT mice based on
mixed linear modeling regression analysis.
TABLE T15 | Phosphatidylcholine lipid species in the cortex of PSAPP mice.
Significant changes in individual species containing phosphatidylcholine. Sample
size for all groups across all time points is n = 4. All data represents mean µM per
(10 mg) wet weight ± SEM. Individual molecular lipid species were quantified by
liquid chromatography/mass spectrometry. Highlighted boxes show significantly
regulated levels (P < 0.001) between PSAPP/WT mice based on mixed linear
modeling regression analysis.
TABLE T16 | Phosphatidylethanolamine lipid species in the cortex of PSAPP
mice. Significant changes in individual species containing
phosphatidylethanolamine. Sample size for all groups across all time points is
n = 4. All data represents mean µM per (10 mg) wet weight ± SEM. Individual
molecular lipid species were quantified by liquid chromatography/mass
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spectrometry. Highlighted boxes show significantly regulated levels (P < 0.001)
between PSAPP/WT mice based on mixed linear modeling regression analysis.
TABLE T17 | Phosphatidylinositol lipid species in the cortex of PSAPP mice.
Significant changes in individual species containing phosphatidylinositol. Sample
size for all groups across all time points is n = 4. All data represents mean µM per
(10 mg) wet weight ± SEM. Individual molecular lipid species were quantified by
liquid chromatography/mass spectrometry. Highlighted boxes show significantly
regulated levels (P < 0.001) between PSAPP/WT mice based on mixed linear
modeling regression analysis.
TABLE T18 | Sphingomyelin lipid species in the cortex of PSAPP mice. Significant
changes in individual species containing sphingomyelin. Sample size for all groups
across all time points is n = 4. All data represents mean µM per (10 mg) wet
weight ± SEM. Individual molecular lipid species were quantified by liquid
chromatography/mass spectrometry. Highlighted boxes show significantly
regulated levels (P < 0.001) between PSAPP/WT mice based on mixed linear
modeling regression analysis.
TABLE T19 | Lysophosphatidylcholine lipid species in the cortex of PSAPP mice.
Significant changes in individual species containing lysophosphatidylcholine.
Sample size for all groups across all time points is n = 4. All data represents mean
µM per (10 mg) wet weight ± SEM. Individual molecular lipid species were
quantified by liquid chromatography/mass spectrometry. Highlighted boxes show
significantly regulated levels (P < 0.001) between PSAPP/WT mice based on
mixed linear modeling regression analysis.
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